Results from a French study of a cohort of individuals with the inherited rare disease Fanconi anemia shed light on how some people with this condition go on to develop secondary leukemia. Writing in the Feb. 2, 2023, issue of Cell Stem Cell, the authors also described some initial tests on cell lines in a mouse model of a drug that has potential to treat individuals with Fanconi anemia who progress to leukemia.
Chan Zuckerberg Biohub and Stanford University have identified cyclin-dependent kinase 19 (CDK19) inhibitors reported to be useful for the treatment of triple-negative breast cancer.
Biogen Inc. and C4 Therapeutics Inc. have patented proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker acting as IRAK-4 degradation inducers reported to be useful for the treatment of cancer, inflammation, autoimmune and metabolic diseases, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and multiple sclerosis, among others.
Several studies on the effect of hyperglycemia on malignant tumor progression have been performed; hyperglycemia is known to be a risk factor for breast cancer-related mortality, since it causes aberrant gene expression by altering the epigenome (hyperglycemic memory).
Mesotheliomas are highly aggressive cancers with short overall survival, which can be extended only by a few months with currently approved therapies. Around 60%-70% of malignant mesotheliomas present mutated or deleted BAP1 tumor suppressor. BAP1 is a catalytic subunit of the polycomb repressive deubiquitinating (PR-DUB) complex, and its loss results in epigenetic alterations.
Sonnet Biotherapeutics Holdings Inc. has completed two IND-enabling toxicology studies in nonhuman primates (NHPs) using its lead bifunctional therapeutic candidate, SON-1210.
Researchers from Zhongnan Hospital of Wuhan University reported data from a study that aimed to evaluate the therapeutic efficiency of organic arsenic compounds for the treatment of osteosarcoma.
Recurv Pharma Inc. is set to receive investment of up to $24 million from TVM Capital Life Science GmbH to support development up to phase IIa proof of concept of RP-001 to treat solid tumors.
New understanding of how prostate cancer adapts to the stress of androgen receptor targeted drugs and becomes castrate-resistant, points to a lesser-studied family of lipid kinases as playing a pivotal role in this process. The findings indicate that specific inhibition of one isoform of these phosphatidylinositol-5-phosphate-4-kinases (PI5P4K) could provide a route to prevent cancer cells altering their metabolism and becoming resistant to androgen deprivation.
Sirnaomics Ltd. is gearing up to start either an expanded phase IIb or a phase III clinical trial for its lead siRNA candidate, STP-705, for the treatment of two non-melanoma skin cancers: squamous cell carcinoma in situ and basal cell carcinoma. STP-705 comprises two siRNA oligonucleotides that inhibit transforming growth factor beta 1 and cyclooxygenase-2 gene expressions and is delivered via injection using what the company describes as a polypeptide nanoparticle-enhanced delivery mechanism.
RSS
